These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Therapy of ischemic and nonischemic heart failure. Current status and prospects]. Weil J; Riegger G Internist (Berl); 2002 Apr; 43 Suppl 1():S8, S11-8. PubMed ID: 11993003 [No Abstract] [Full Text] [Related]
29. Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations. Rahimtoola SH Eur Heart J; 2006 Jul; 27(13):1630; author reply 1630-1. PubMed ID: 16760215 [No Abstract] [Full Text] [Related]
30. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Follath F; Franco F; Cardoso JS Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827 [TBL] [Abstract][Full Text] [Related]
31. Levosimendan: a new dual-action drug in the treatment of acute heart failure. Mebazaa A; Erhardt L Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347 [TBL] [Abstract][Full Text] [Related]
32. [Cardiac failure in the geriatric patient]. Werner H MMW Fortschr Med; 2006 Mar; 148(12):34, 36-8, 40. PubMed ID: 16626004 [TBL] [Abstract][Full Text] [Related]
33. Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. Felker GM; O'connor CM Am Heart J; 2001 Dec; 142(6):932-3. PubMed ID: 11717593 [No Abstract] [Full Text] [Related]
34. The value of intermittent inotropic therapy in unhospitalized patients with refractory heart failure. Moga VD; Luca C; Luca CT; Branea H; Drăgulescu SI Rom J Intern Med; 1999; 37(1):25-9. PubMed ID: 15523942 [TBL] [Abstract][Full Text] [Related]
35. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D; Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942 [TBL] [Abstract][Full Text] [Related]
36. Hydralazine and nitrates: beyond race and ethnicity. Ghali JK J Card Fail; 2007 Apr; 13(3):238. PubMed ID: 17448423 [No Abstract] [Full Text] [Related]
37. [Erythropoietin in the treatment of heart failure and ischemia]. Lewartowski B Kardiol Pol; 2007 Feb; 65(2):192-7. PubMed ID: 17366366 [No Abstract] [Full Text] [Related]
38. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
39. Istaroxime in heart failure new hope or more hype. Dec GW J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277 [No Abstract] [Full Text] [Related]
40. [Anabolic agents in the therapy of chronic circulatory failure]. Bondarenko IP Vrach Delo; 1982 Sep; (9):52-5. PubMed ID: 6758353 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]